In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy (Q26741365)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy	scientific article

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy (English)

0 references

0 references

4

object named as

Helen McShane

0 references

author name string

Rachel Tanner

1

0 references

Matthew K O'Shea

2

0 references

Helen A Fletcher

3

0 references

language of work or name

0 references

publication date

7 September 2016

0 references

0 references

34

0 references

39

0 references

4656-65

0 references

Immune markers and correlates of protection for vaccine induced immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Disseminated tuberculosis in interferon gamma gene-disrupted mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

T-cell activation is an immune correlate of risk in BCG vaccinated infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Inhibition of virulent Mycobacterium tuberculosis by murine peritoneal macrophages and human alveolar lavage cells: the effects of lymphokines and recombinant gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Effectiveness of BCG vaccination in England and Wales in 1983.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

The epidemiology of tuberculosis infection in a closed environment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guérin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

A functional whole blood assay to measure viability of mycobacteria, using reporter-gene tagged BCG or M.Tb (BCGlux/M.Tb lux).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Optimisation of a functional mycobacterial growth-inhibition assay to improve its suitability for infant TB vaccine studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Novel human in vitro system for evaluating antimycobacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

A whole blood bactericidal assay for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Variation in protection by BCG: implications of and for heterologous immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Cellular responses and Mycobacterium bovis BCG growth inhibition by bovine lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Ability of T cell subsets and their soluble mediators to modulate the replication of Mycobacterium bovis in bovine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

A practical in vitro growth inhibition assay for the evaluation of TB vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Gammadelta T cells and Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Granzyme A produced by γ(9)δ(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

The Achilles heel of BCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Granulysin: a lethal weapon of cytolytic T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Identification of nitric oxide synthase as a protective locus against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

B cells and antibodies in the defense against Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Tuberculin-sensitivity and antibodies (agglutinins) after BCG-vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Humoral immune response in infants after BCG vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Detection of antibodies to Mycobacterium tuberculosis plasma membrane antigen by enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Bovine dendritic cells are more permissive for Mycobacterium bovis replication than macrophages, but release more IL-12 and induce better immune T-cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Constrained Intracellular Survival of Mycobacterium tuberculosis in Human Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Dendritic Cells Are Host Cells for Mycobacteria In Vivo That Trigger Innate and Acquired Immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Neutrophil-mediated innate immune resistance to mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Neutrophils in tuberculosis: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Human NK cells positively regulate gammadelta T cells in response to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

A mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

The Influence of Remaining Live BCG Organisms in Vaccinated Mice on the Maintenance of Immunity to Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Differential signaling of inducible nitric oxide synthase induction in Mycobacterium tuberculosis infected alveolar epithelial cell line A549 in response to cytokines IFN-γ, TNF-α and IL-1β.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.058

7 January 2021

A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity

1 reference

15 October 2024

https://opencitations.net/index/api/v1/citations/10.14573/ALTEX.1311041

Identifiers

10.1016/J.VACCINE.2016.07.058

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26741365&oldid=2260981338"